Work

Phase 1 study of combinatorial sorafenib, G‐CSF , and plerixafor treatment in relapsed/refractory, FLT3‐ITD ‐mutated acute myelogenous leukemia patients

Year: 2020

Type: article

Study design: Clinical Trial

Source: American Journal of Hematology

DOI: 10.1002/ajh.25943

Authors: Gautam Borthakur, Zhihong Zeng, Jorge E. Cortes, Hsiang‐Chun Chen, Xuelin Huang, Marina Konopleva, Farhad Ravandi, Tapan Kadia, Keyur P. Patel, Naval Daver, Mary A. Kelly, Teresa McQueen, Ru‐Yiu Wang, Hagop Kantarjian, Michael Andreeff

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Foundation for the National Institutes of Health

Awards: G112279217, G120902818, G1990399159, G545455019

OpenAlex ID: W3045209514

FWCI: 2.995

Cites: 35

Cited by: 39

Related to: 10